Pomerantz Law Firm Initiates a Class Action Against Savara Inc. for Alleged Securities Violations

Pomerantz Law Firm Takes Action Against Savara Inc.

On September 23, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against Savara Inc. (NASDAQ: SVRA) and certain officers of the company. The lawsuit, which has been filed in the United States District Court for the Eastern District of Pennsylvania under docket number 25-cv-05147, represents all individuals and entities who acquired Savara securities between March 7, 2024, and May 23, 2025—period during which the alleged violations of federal securities laws occurred.

This legal action aims to recover damages resulting from misconduct by Savara executives. Investors who purchased Savara securities during this period have until November 7, 2025, to contact the court and request to be appointed as Lead Plaintiff for the class. Pomerantz encourages interested parties to reach out via email or phone to discuss the case. More details and a copy of the complaint can be accessed at Pomerantz Law's website.

Savara Inc. is a biopharmaceutical firm focusing on treatment options for rare respiratory diseases, with its leading product candidate being MOLBREEVI (molgramostim), which is currently in a pivotal Phase 3 clinical trial targeting autoimmune pulmonary alveolar proteinosis (aPAP). This rare lung condition is marked by an unusual accumulation of surfactant in the lungs, leading to serious health complications.

In recent statements, Savara has maintained a narrative of strong fiscal health, asserting it is well-capitalized through at least 2026, bolstered by investments in its flagship product, MOLBREEVI. In December 2024, the company commenced a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, highlighting expected positive outcomes from the IMPALA-2 trial. However, several allegations have arisen suggesting that Savara misrepresented the completeness of its BLA, particularly concerning critical areas such as chemistry, manufacturing, and controls (CMC), which could significantly impact the approval timeline and the company’s financial stability.

As the class period unfolded, several statements issued by Savara indicated a commitment to complete the BLA submission by early 2025. However, on May 27, 2025, the firm alerted the market to a major setback: the FDA had issued a 'refusal to file' letter, stating that the application was incomplete. This announcement introduced skepticism among analysts and investors alike, with Guggenheim revising its price target for Savara’s stock from $9.00 to $8.00. This marked a pivotal shift in investor sentiment, contributing to a significant drop in Savara's stock price, which plummeted 31.69% from $2.84 to $1.94 in just one day.

The aftermath of this announcement revealed further discrepancies in Savara’s previous claims. An earnings report released on August 13, 2025, indicated that the company now expected to resubmit the BLA in December 2025, which was a stark contrast to their original forecast.

Pomerantz LLP has a long history of advocating for victims of corporate fraud and has successfully recovered billions of dollars for class members through its extensive litigation experience. The firm is recognized as a leading player in corporate and securities class actions, founded by Abraham L. Pomerantz, who pioneered this area of law over 85 years ago.

If you're one of the investors affected by this situation, it's critical to understand your rights and the implications of this lawsuit. Pomerantz remains committed to unraveling the truth and seeking justice for those wronged by corporate misconduct. For more personalized guidance related to this case, interested parties are encouraged to reach out directly to the firm and provide relevant details. Given the complexities of securities class actions, timely participation could be pivotal in navigating these legal waters effectively.